A Randomized Controlled Trial of Mecobalamin Injection and Tablet Treatment Efficacy on Mild to Moderate Diabetic Peripheral Neuropathy

NCT ID: NCT04372316

Last Updated: 2020-05-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-12-25
• Study Completion Date: 2021-12-31

Brief Summary

To evaluate the efficacy of mecobalamin injection and tablet in the treatment of small fiber lesions in the early stage of diabetic peripheral neuropathy by corneal confocal microscopy.

Conditions

Diabetic Neuropathies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

methylcobalamin injection

Group Type: ACTIVE_COMPARATOR

methylcobalamin

Intervention Type: DRUG

methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks

methylcobalamin tablet

Group Type: ACTIVE_COMPARATOR

methylcobalamin

Intervention Type: DRUG

methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks

Interventions

methylcobalamin

methylcobamin injection 8 weeks or tablet 8 weeks， followed by 24 weeks methylcobamin tablet until 32 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• diagnosis of type 1 or 2 diabetes for at least 1 year
• must be consistent with the diagnosis of distal, symmetrical, sensorimotor polyneuropathy
• according to the clinical judgment of the researchers, the blood glucose has been under the best control. Before screening visit, HbA1c level ≤ 9%. During the course of the study, the blood glucose was adjusted under the guidance of the researchers, and the blood glucose was kept stable as much as possible.
• Toronto clinical neuropathy score (TCSs) ≤ 5 at screening visit
• no history of eye injury and laser treatment
• no history of keratopathy or other intraocular and extraocular diseases
• no wearing history of corneal contact lens
• no drugs affecting corneal metabolism
• no Mecobalamin or lipoic acid in 3 months
• women of childbearing age (e.g. non-surgical contraception or menopause less than 1 year) must be negative in the gonadotropin pregnancy test (urine) during the screening period, and effective contraceptive measures must be taken during the treatment period and within 1 month after the end of the treatment
• the participant signs the informed consent, indicating that the subject has been informed of all research related contents
• participants are willing and able to follow study visit arrangements, treatment plans, laboratory tests and other research procedures

Exclusion Criteria

• has been diagnosed as a malignant tumor in the past 2 years.
• the presence of other neurological disorders that the researchers believe may affect the evaluation of diabetic peripheral neuropathy
• presence of skin disease in the affected skin area, which, in the judgment of the researchers, may affect the evaluation of diabetic peripheral neuropathy
• amputations other than finger ends and toes
• participated in any other studies or post market drugs studies within 30 days prior to screening
• participants with clinically significant or unstable diseases, such as but not limited to acute cardiovascular disease, cerebrovascular disease, liver, kidney, respiratory system, blood system, immune system, inflammatory or rheumatic disease, uncontrolled infection, symptomatic peripheral vascular disease, untreated endocrine disease, etc
• have donated blood within 30 days prior to the start of the study treatment (if applicable); or have prepared blood donors during the study or within 30 days after the end of the treatment
• WBC < 4000 / mm3; neutrophil count < 1500 / mm3; platelet count < 100 × 103 / mm3
• clinically significant abnormal 12 lead ECG
• participants received combined transcutaneous electrical nerve stimulation (TENS) or acupuncture
• previous history of intolerance or allergies to study drugs or drugs with similar chemical structure
• has a history of alcohol and / or other drug abuse in the past year or is currently under the influence of alcohol or drug abuse
• the presence of other acute or chronic medical or psychiatric conditions or laboratory abnormalities that, in the judgment of the investigator, may increase the risk associated with participating in the trial or using the study product, or may affect the interpretation of the study results, may make the subject unsuitable for the trial
• inability and / or unwillingness to understand and / or comply with the program

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Fan Dongsheng

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Peking University Third Hospital

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Dongsheng Fan

Role: CONTACT

dsfan2010@aliyun.com

+86 010 82265694

Facility Contacts

Dongsheng Fan

Role: primary

References

Zhang Y, Fan D, Zhang Y, Zhang S, Wang H, Liu Z, Wang H. Using corneal confocal microscopy to compare Mecobalamin intramuscular injections vs oral tablets in treating diabetic peripheral neuropathy: a RCT. Sci Rep. 2021 Jul 19;11(1):14697. doi: 10.1038/s41598-021-94284-4.

Reference Type: DERIVED

PMID: 34282267 (View on PubMed)

Other Identifiers

PUTH2017286

Identifier Type: -

Identifier Source: org_study_id